Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology.
BridGene strikes another partnership with Takeda as the latter company continues its dealmaking streak, following high-ticket ...
9h
GlobalData on MSNEMA approves Takeda’s Takhzyro pre-filled pen option for HAEThe current approval of Takeda’s Takhzyro pre-filled pen is an addition to the existing 150 mg and 300 mg pre-filled syringes ...
Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well ...
Takeda, a global biopharmaceutical company with a manufacturing site in Stanton Springs, unveiled its new Biomedical Waste ...
Takeda’s plasma-derived therapies (PDT) business tackles supply-chain challenges to expand access to life-saving treatments, ...
BridGene Biosciences Inc. has entered a strategic collaboration and licensing agreement with Takeda through which it will use ...
Zurich: Takeda has announced that the European Medicines Agency (EMA) has given approval for an additional 2 mL pre-filled ...
Takeda (TAK) announced that the EMA has approved an additional two mL pre-filled pen option for Takhzyro for subcutaneous administration in ...
TOKYO (Reuters) -Takeda Pharmaceutical said on Thursday its CEO Christophe Weber will retire after more than a decade at the helm of Japan's biggest drugmaker as the company upped its full-year ...
12h
Hosted on MSN'His Inspiration Was No Longer as Strong': Dragon Ball Editors Reveal Akira Toriyama's Burnout Writing DBZDragon Ball's former editors discuss the legacy of the late Akira Toriyama and how his passion for the series diminished near ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results